Alpha Thalassemia Market Trends by Types and Application | Forecast Analysis To 2023
Market Outlook
Thalassemia
is a hereditary blood disorder in which a person’s body makes an abnormal form
of hemoglobin, which is the protein molecule in red blood cells (RBCs),
carrying oxygen. The disorder results in unwarranted damage to red blood cells,
which leads to anemia. Anemia is a condition in which the body doesn’t have an
adequate amount of normal and healthy red blood cells. There are majorly two
types of thalassemia based on the proteins known as the Alpha thalassemia and
the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia,
which is like a combination of sickle cell disease and beta thalassemia.
The
global market for alpha thalassemia is expected to grow at a CAGR of
approximately 8.8% during the forecast period 2017-2023.
Even
though it is a rare genetic disorder, the number of people affected by it has
been growing with time. While those with alpha thalassemia minor have hardly
any threat to their life and only require an occasional blood transfusion to
sustain, thalassemia major patients need to go for periodic transfusions for a
sustained life.
Get Free Sample Copy at https://www.marketresearchfuture.com/sample_request/5148
Segmentation
The alpha thalassemia is segmented on the basis of
type, diagnosis, treatment, and end-users.
On the
basis of the type, the market is segmented into hemoglobin
Bart hydrops fetalis syndrome or Hb Bart syndrome (the more severe form), HbH
disease, silent carrier state, and trait.
On the
basis of the diagnosis, the market is segmented into perinatal
testing, prenatal testing, and pre-implantation. Further, the perinatal testing
sub-categorized into complete blood count (CBC) And DNA testing. The prenatal
testing segment is divided into Prenatal Genetic Testing and Chorionic Villus
Sampling.
On the
basis of the treatment, the market is segmented into blood
transfusions, iron chelation, bone marrow, or stem cell transplant, surgery and
gene therapy.
On the
basis of the end-user, the market is segmented into hospitals,
biotechnological laboratories, diagnostic laboratories, educational research
institutes, pharmaceutical industries and others.
In case
of infants, thalassemia major often leads to still birth or cause death shortly
after the baby’s birth. Presently the only cure for alpha thalassemia is a bone
marrow transplantation therapy, which is done mostly for severe cases of alpha
thalassemia.
Table
Of Content
1.
Report Prologue
2.
Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3.
Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4.
Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5.
Market Factor Analysis
5.1 Porters Five Forces Analysis
5.2 Value Chain Analysis
…continued
Brows
Complete Premium Research at https://www.marketresearchfuture.com/reports/alpha-thalassemia-market-5148
Key
Players
The other key players include Pharmaceuticals Inc,
Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas
Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences
Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson
& Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck &
Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics
Inc and Zydus Cadila Healthcare Ltd.
Regional
Analysis
Globally, the alpha thalassemia market comprises of
Americas, Europe, Asia Pacific, and the Middle East and Africa.
North America is projected to hold the largest share
followed by Europe. The testing market for alpha thalassemia has a growing
trend in the countries with ethnic groups like Mediterranean countries, African
countries and few countries in Asia Pacific. As migration has become more
common, the population of alpha thalassemia can be seen rising in the developed
countries as well. There are several prenatal tests available on the market to
determine the possibility of alpha thalassemia including both invasive and
non-invasive technique. A recent advancement in the testing of alpha
thalassemia may determine the risk of the disease by in vitro examination of
the embryo. Even though there are many such testing available in the market but
lack of awareness leads to the negligence and delayed diagnosis of the diseased
state.
And Many More.
Inquire
for any Query at https://www.marketresearchfuture.com/enquiry/5148
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
In
order to stay updated with technology and work process of the industry, MRFR
often plans & conducts meet with the industry experts and industrial visits
for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Comments
Post a Comment